Lice Infestation market Expected to Exhibit a CAGR of 4.74% during 2025-2035, Impelled by Rising Health Concerns and Hygiene Awareness

Lice Infestation Market Outlook 2025-2035:

The 7 major lice infestation market are expected to exhibit a CAGR of 4.74% during 2025-2035. The The Lice Infestation market is increasingly driven by the adoption of non-invasive and minimally invasive treatment options that offer effective, convenient, and safe solutions for managing and eliminating lice infestations. Products such as medicated shampoos, topical lotions, and combing treatments are becoming popular for their ease of use, reduced side effects, and effectiveness in managing lice. Additionally, thermal devices that use heat to kill lice and their eggs have gained popularity. These non-chemical treatments not only help to eliminate lice but also reduce the risk of skin irritation and chemical exposure, offering a safer alternative for both children and adults. Essential oil-based treatments like tea tree oil and coconut oil are also being increasingly adopted for their natural lice-removal properties, attracting those seeking non-toxic, eco-friendly options.

Advances in Early Detection and Diagnostic Technologies: Driving the Lice Infestation Market 

Modern diagnostic and treatment technologies are significantly changing the Lice Infestation market, through better management and improvement of patient outcome. Advanced diagnostic tools such as scalp imaging technologies provide detailed visual assessments that allow for the monitoring of precise lengths of lice and nits in order to ensure accurate planning of treatment. These innovations make it possible to take a better targeted approach toward infestation determination and identification of effective treatments. Molecular diagnostics, such as PCR tests and DNA sequencing, are more frequently applied to identify lice species and resistance to specific drugs with precisely targeted therapies. Furthermore, AI-based diagnostic tools can be used in the future for automatic screening of infestation through scalp images instead of the subjective evaluation systems. Thermal devices, essential oil-based treatments, medicated shampoos, and other non-invasive treatments are becoming increasingly popular. Such technologies are more effective, chemical-free, and less risky for the patient, particularly in the presence of children. Some newer products use heat or air to get rid of the lice and nits; this does not cause too much discomfort and the need for toxic chemicals is not significant. Novel wearable technologies, such as smart lice combs or smart patches, will enable real-time monitoring of lice infestations, thus ensuring more personalized care and quicker intervention. Such devices can help in detecting early signs of reinfestation, thus allowing for timely treatment and reducing the need for multiple visits to healthcare providers. Telemedicine platforms also have a very important role in enhancing access to lice management solutions, including remote consultations and treatment guidance for patients in areas where dermatologists or specialized care are not easily accessible. This helps ensure that infestations of lice are addressed promptly and effectively, thereby enhancing patient outcomes while minimizing the psychological distress or inconvenience of repeated treatments.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The market for Lice Infestation is growing due to new therapies and advanced pharmacological treatments. New topical and oral agents are being designed to tackle resistant lice strains that have developed and which are causing increasing failures with traditional therapeutic methods. These new treatments are more effective, exhibit fewer side effects, and offer a targeted approach resulting in higher patient outcomes and increased patient satisfaction result. Research into biological treatments for Lice Infestation is expanding, especially in chronic or severe cases. The use of monoclonal antibodies that neutralize key inflammatory cytokines will address not only the inflammation resulting from lice infestations but also the underlying immune response responsible for the persistence of these conditions. Such biologics can help manage the lice infestation, skin irritation, and secondary infections often associated with these conditions. Advances in drug delivery systems, such as liposomal formulations, hydrogels, and nanotechnology-based carriers, are enabling more precise and localized delivery of treatments. These inventions increase the local concentrations of the therapeutic agents and consequently decrease the systemic exposure of patients to them. Thus, these reduce the chance of causing harmful side effects on patients, especially children or people with sensitive skin. Novel additional treatments that may assist in readjusting the balance of microbes in the scalp that gets distorted due to the presence of lice infestations are under development. These comprise probiotics and immunomodulators, intended to boost the scalp's endogenous defenses, while reducing inflammation. Combination treatments involving antimicrobials, anti-inflammatory drugs, or innovative formulations of topical drugs are found to be quite promising in dealing with the multi-factorial causes of lice infestation. Another non-invasive pharmaceutical drug includes biofilm-disrupting agents, as these are convenient to apply and are patient-centered. These solutions provide patients with convenient treatments, reducing the need for multiple visits and long treatment times, while ensuring effective management of lice infestations.

Marketed Therapies in Lice Infestation Market

Natroba (Spinosad): Eli Lilly and Company/ParaPRO

Natroba (spinosad) is a prescription drug that is used to treat head lice infestations. It works by affecting the nervous system of lice, leading to paralysis and death. Natroba is applied topically and kills both lice and their eggs, making it a convenient and non-toxic way to manage lice infestations.

Sklice (Ivermectin topical): Sanofi

Sklice, also known as ivermectin, is a prescription topical drug used in the treatment of head lice infestations in patients greater than or equal to 6 months old. This is done by paralyzing and killing lice, offering one application with minimal risk of side effects. Sklice is especially helpful because it is easy to apply and can be targeted at both lice and eggs simultaneously, allowing the infestation to be killed in fewer applications.

Ulesfia (Benzyl alcohol): Shionogi Pharma

Ulesfia, or benzyl alcohol lotion, is a prescription topical that can be applied to patients of six months of age and above for the management of head lice infestation. It functions by asphyxiating the lice so that they are not able to sustain their essential cellular functions. It is a one-time application product with fewer side effects compared to other drugs for lice treatment.

Xeglyze (Abametapir): Hatchtech

Xeglyze (abametapir) is a topical drug that has been approved for the treatment of head lice infestations in patients aged 6 months and older. It functions by inhibiting the enzymes that are necessary for the survival and development of lice, and it is non-pesticidal, providing a single application that is effective in eliminating the lice and their eggs. Xeglyze is an important addition to the lice infestation treatment market because of its efficacy and minimal side effects.

Leading Companies in the Lice Infestation Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global Lice Infestation market, several leading companies are at the forefront of developing integrated platforms to enhance the management of Lice Infestation. Some of the major players include Hatchtech, Shionogi Pharma, Eli Lilly and Company/ParaPRO, Sanofi, and others. These companies are driving innovation in the Lice Infestation market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for Lice Infestation.

​In October 2020, the U.S. Food and Drug Administration (FDA) approved Sklice (ivermectin) lotion, 0.5%, for over-the-counter (OTC) use, following a prescription (Rx)-to-OTC switch. Previously, the FDA had approved Sklice as a prescription treatment for head lice infestations in patients aged 6 months and older.

Key Players in Lice Infestation Market:

The key players in the Lice Infestation market who are in different phases of developing different therapies are Hatchtech, Shionogi Pharma, Eli Lilly and Company/ParaPRO, Sanofi, and Others.

Regional Analysis:

The major markets for Lice Infestation include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for Lice Infestation while also representing the biggest market for its treatment. New treatments in the Lice Infestation market are emerging with advanced topical agents, biofilm-disrupting formulations, and new anti-parasitic drugs that improve the effectiveness of eliminating lice. These treatments tackle the challenges of resistance, with more targeted therapies that minimize adverse reactions and ensure quicker, more efficient results. Technologies such as ivermectin-based products and novel insecticidal formulations have proven to be more promising in overcoming previous limitations, while minimizing risks associated with traditional chemical treatments.

Diagnostic tools have become more advanced in terms of detecting infestations with the invention of rapid lice detection systems, allowing early intervention and, consequently, lesser transmission. In conjunction with this, AI-driven tools help in real-time tracking and monitoring of infestations, making for more individualized treatment plans. Telemedicine also plays a huge role, allowing for remote consultation and treatment services, especially where healthcare facilities are not easily accessible. Other factors that add to the Lice Infestation market growth include increasing awareness, regulatory approvals of new treatments, and investment in research and development. The innovative activities are spurred by collaborations among pharmaceutical companies, technology providers, and research institutes. As new, more advanced therapies and diagnostic tools emerge, North America and Europe will remain at the helm of driving further market expansion in this region toward global growth.

Recent Developments in Lice Infestation Market:

• In July 2020, The U.S. Food and Drug Administration (FDA) has authorized Xeglyze (abametapir) for the treatment of head lice infestations in patients 6 months of age and older.

Key information covered in the report

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

 Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Lice Infestation market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Lice Infestation market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current Lice Infestation marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

 Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800